PedAM
Pediatric Disease Annotations & Medicines
| Disease | arteriosclerosis |
| Phenotype | C0085580|essential hypertension |
| Sentences | 8 |
| PubMedID- 23787071 | Set a cut-off value of cfpwv at ≥ 9 m/s to diagnose arteriosclerosis in patients with essential hypertension [31] and more recently 10 m/s has been proposed as the threshold above which there is an increased risk of cardiovascular events [27]. |
| PubMedID- 23124356 | The aim of this study was to investigate the association between myeloperoxidase (mpo) gene polymorphisms and carotid atherosclerosis (as) in patients with essential hypertension (eh). |
| PubMedID- 23031621 | Impaired endothelial function is observed in subjects with risk factors for atherosclerosis and in patients with essential hypertension [2,5,6]. |
| PubMedID- 25496381 | Asymmetric dimethylarginine is associated with carotid atherosclerosis in patients with essential hypertension. |
| PubMedID- 20144068 | The cimt was negatively correlated with hdl antioxidative activity, which suggests that decreased hdl antioxidative activity may be one of the important determinants for the development of atherosclerosis in patients with essential hypertension. |
| PubMedID- 23525413 | Ample clinical data demonstrate that circulating aldo levels are independent predictors of cardiovascular ischemia.39–40 patients with primary hyperaldosteronism have a 4‐fold increased risk of stroke and a 6‐fold increased risk of myocardial infarction (mi) when compared with patients with the same degree of essential hypertension.9 in patients with atherosclerosis, higher serum aldo levels—even within the normal range—predict a 2‐ to 4‐fold increase in subsequent mi or cardiovascular death,8 and in patients with dyslipidemia, the recent failure of the hdl‐raising drug torcetrapib was associated with an off‐target increase in serum aldo levels that correlated with an increased rate of mi, stroke, and progression of atherosclerosis.10–12,10–43 conversely, drugs that prevent aldo production (angiotensin‐converting enzyme inhibitors or angiotensin receptor blockers) or that inhibit aldo action (mr antagonists) reduce the risk of cardiovascular events and death out of proportion to small reductions in blood pressure (reviewed in ref. |
| PubMedID- 24301778 | Association of paraoxonase polymorphisms with carotid artery atherosclerosis in essential hypertension patients. |
| PubMedID- 22701508 | The cavi was also reported to be a useful clinical marker for evaluating atherosclerosis and arteriolosclerosis in patients with essential hypertension [19]. |
Page: 1